Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Chim, Chor S ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEATH ASSOCIATED PROTEIN KINASE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BORONIC ACID DERIVATIVE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; DEATH-ASSOCIATED PROTEIN KINASE; PYRAZINE DERIVATIVE;

ADULT; AGE; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; EVENT FREE SURVIVAL; FACTORIAL ANALYSIS; FEMALE; FOLLOW UP; GENDER; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN METHYLATION; SURVIVAL RATE; SURVIVAL TIME; AUTOTRANSPLANTATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYMOLOGY; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; BORONIC ACIDS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FACTOR ANALYSIS, STATISTICAL; HUMANS; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; PYRAZINES; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 78649327381     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-124     Document Type: Article

References (19)

1. Chim CS, Hwang YY, Pang C, Shek TW. Restoration of chemosensitivity by Bortezomib: implications for refractory myeloma. Nat Rev Clin Oncol 2009, 6:237-240. 10.1038/nrclinonc.2009.15, 19333230.
2. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-17. 10.1056/NEJMoa030288, 12826635.
3. Popat R, Oakervee HE, Hallam S, Curry N, Odeh L, Foot N, Esseltine DL, Drake M, Morris C, Cavenagh JD. ortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol 2008, 141. 10.1111/j.1365-2141.2008.06997.x, 18371113.
4. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359. 10.1056/NEJMoa0801479, 18753647.
5. Chim CS, Lie AK, Chan EY, Leung YY, Cheung SC, Chan SY, Liang R, Kwong YL. A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma. Ann Hematol 2010, 89. 10.1007/s00277-010-0959-4, 2924968, 20428873.
6. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol 2005, 23.
7. Chim CS, Liang R, Tam CY, Kwong YL. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol 2001, 19.
8. Chim CS, Liang R, Kwong YL. Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol 2002, 20. 10.1002/hon.694, 12469326.
9. Chim CS, Fung TK, Cheung J, Liang R Kwong YL. SOCS1 and SHP1 Hypermethylation in Multiple Myeloma: Implications for Epigenetic Activation of the Jak/STAT pathway. Blood 2004, 103.
10. Chim CS, Liang R, Fung TK, Choi CL, Kwong YL. Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol 2007, 60.
11. Chim CS, Fung TK, Wong KF, Lau JS, Liang R. Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic lymphocytic leukemia. J Hum Genet 2006, 51. 10.1007/s10038-006-0029-x, 16897188.
12. Chim CS, Chan WW, Kwong YL. Epigenetic dysregulation of the DAP kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in acute leukaemias. J Clin Pathol 2008, 61.
13. Chim CS, Wong SY, Kwong YL. Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and prognostic significance. Br J Haematol 2003, 122. 10.1046/j.1365-2141.2003.04462.x, 12899712.
14. Chim CS, Chan WW, Pang A, Kwong YL. Preferential methylation of Wnt inhibitory factor-1 in acute promyelocytic leukemia: an independent poor prognostic factor. Leukemia 2006, 20.
15. Chim CS, Lau JS, Wong KF, Kwong YL. CDKN2B methylation is an independent poor prognostic factor in newly diagnosed acute promyelocytic leukemia. Leukemia 2006, 20.
16. Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, García-Laraña J, Martínez-Martínez R, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernández-Ruiz B, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008, 26.
17. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359. 10.1056/NEJMoa0801479, 18753647.
18. Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, Kolb B, Macro M, Campion L, Wetterwald M, Stoppa AM, Hulin C, Facon T, Attal M, Minvielle S, Harousseau JL. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010, 28.
19. Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S, Ely S, Mazumdar M, Cesarman E, Leonard JP, Furman RR, Chen-Kiang S, Niesvizky R. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. Br J Haematol 2008, 143. 10.1111/j.1365-2141.2008.07374.x, 18950461.